PRVB Stock Recent News

Sanofi plans to acquire Provention Bio for around $2.9 billion. The deal will add Provention's type 1 diabetes drug Tzield to Sanofi's lineup.

Provention Bio (PRVB) to be acquired by pharma-giant Sanofi (SNY) for $2.9 billion. The transaction is likely to close by second-quarter 2023.

Provention Bio (NASDAQ: PRVB ) stock is rocketing higher on Monday following news that Sanofi (NASDAQ: SNY ) is acquiring the company. That deal has Sanofi agreeing to acquire Provention Bio for $25 per share in cash.

RED BANK, N.J. , March 13, 2023 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced it has cancelled the release of its fourth quarter and full year financial results for the period ended December 31, 2022 due to the announcement earlier today that Provention has entered into a definitive agreement to be acquired by Sanofi, Provention's U.S. TZIELD co-promotion partner, subject to customary regulatory and other closing conditions.

RED BANK, N.J. , Feb. 23, 2023 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that it will report its fourth quarter and full year 2022 financial results on Thursday, March 16, 2023, before the opening of the U.S. financial markets.

PRVB got its teplizumab approved last year. The molecule is a wonderful new addition to T1D therapy; however, it has been in development for decades.

There is an argument for hitting the buy button, but it's important to consider the potential risks too.